Jamie Layland

Jamie Layland


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
LDLuke P. Dawson
Luke P. Dawson
JLJamie Layland
Jamie Layland
Advances in coronary plaque imaging over the last few decades have led to an increased interest in the identification of novel high-risk plaque features that are associated with cardiovascular events. Existing practices focus on risk stratification and lipid monitoring for primary and secondary prevention of cardiac events, which is limited by a lack of assessment and treatment of vulnerable plaque. In this review, we summarize the multitude of studies that have identified plaque, haemodynamic and patient factors associated with risk of acute coronary syndrome. Future progress in multi-modal imaging strategies and in our understanding of high-risk plaque features could expand treatment options for coronary disease and improve patient outcomes.

1 January 2009 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
JLJamie Layland
Jamie Layland
CJChristine Jellis
Christine Jellis
RWRobert Whitbourn
Robert Whitbourn

1 August 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
JLJamie Layland
Jamie Layland
AWAndrew M. Wilson
Andrew M. Wilson
RWRobert J. Whitbourn
Robert J. Whitbourn
ABAndrew T. Burns
Andrew T. Burns
JSJithendra Somaratne
Jithendra Somaratne
AMAndrew I. MacIsaac
Andrew I. MacIsaac

14 November 2015 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
JNJulian Nam
Julian Nam
ABAndrew Briggs
Andrew Briggs
JLJamie Layland
Jamie Layland
KOKeith G. Oldroyd
Keith G. Oldroyd
NCNick Curzen
Nick Curzen
CBColin Berry
Colin Berry
In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coronary revascularisation, compared to visual interpretation of standard coronary angiography without FFR. We estimated the cost-effectiveness from a UK National Health Service perspective, based on the results of FAMOUS. A mixed trial- and model-based approach using decision and statistical modelling was used. Within-trial (1-year) costs and QALYs were assembled at the individual level and then modelled on subsequent management strategy [coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical therapy (MT)] and major adverse coronary events (death, MI, stroke and revascularisation). One-year resource uses included: material, hospitalisation, medical, health professional service use and events. Utilities were derived from individual EQ5D responses. Unit costs were derived from the literature. Outcomes were extended to a lifetime on the basis of MACE during the 1st year. Costs and QALYs were modelled using generalized linear models whilst MACE was modelled using logistic regression. The analysis adopted a payer perspective. Costs and outcomes were discounted at 3.5 %. Costs were related to the subsequent management strategy and MACE whilst QALYs were not. FFR led to a modest cost increase, albeit an imprecise increase, over both the trial [£112 (−£129 to £357)] and lifetime horizons [£133 (−£199 to £499)]. FFR led to a small, albeit imprecise, increase in QALYs over both the trial [0.02 (−0.03 to 0.06)] and lifetime horizons [0.03 (−0.21 to 0.28)]. The mean ICER was £7516/QALY and £4290/QALY over the trial and lifetime horizons, respectively. Decision remained high; FFR had 64 and 59 % probability of cost-effectiveness over trial and lifetime horizons, respectively. FFR was cost-effective at the mean, albeit with considerable decision uncertainty. Uncertainty can be reduced with more information on long-term health events.

1 January 2012 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
JLJamie Layland
Jamie Layland
RWRobert Whitbourn
Robert Whitbourn
AMAndrew MacIsaac
Andrew MacIsaac
JSJithendra Somaratne
Jithendra Somaratne
AWAndrew Wilson
Andrew Wilson

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
JLJamie Layland
Jamie Layland
CJChris Judkins
Chris Judkins
SPSonny Palmer
Sonny Palmer
RWRob Whitbourn
Rob Whitbourn
AWAmy Wilson-O'Brien
Amy Wilson-O'Brien
AWAndrew Wilson
Andrew Wilson